Praeventix
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
770 Pennsylvania Dr Ste 100, Exton, Penn...Phone Number
(610) 458-5625Website
www.praeventix.comRevenue
$9.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Praeventix
Praeventix was founded by Dr. Douglas Pippin based on discoveries he researched at Temple University. The company is initially focused on the development of pre-clinical candidate PRA-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. In addition, the company is researching 5-HT7 modulators for the potential treatment of cocaine use disorder (CUD). Potential first indicationExplore more
Popular SearchesPraeventix LLCPraeventixSIC Code 87,873NAICS Code 54,541Show more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Praeventix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Praeventix has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Praeventix
Praeventix, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Praeventix has new funding data
Check out if Praeventix is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Praeventix launches new products
Click to see if Praeventix had a recent Job posting/layoffs
Earning: See what the market has to say on Praeventix recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Praeventix as Masked Content
Find more new buyers
Compare Similar Companies to Praeventix
Compare insights from companies similar to Praeventix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Praeventix
$9.9M
11-50
Private
<$5M
-
N/A
Company Profile Activity
Activity Insights
Praeventix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Praeventix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Praeventix.
Praeventix financials insights
Gather financial insights about Praeventix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$69K
2026
Private Equity
$3M
Praeventix Tech Stack
A closer look at the technologies used by Praeventix
Most Recent Scoops
Funding
Funding
Funding
Project
received an award of $1,250,000 on August 1, 2023 by HHS NIH with an award end date of May 31, 2025. This award will support efforts focused on developing selective 5-HT7 receptor antagonists to enhance extinction learning and reduce cocaine reinstatement, aiming to offer a novel pharmacotherapy for treating cocaine use disorder..
Product Development, Research & Development, Medical Research, Clinical Operations, Operations
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations, Operations
Funding
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Praeventix
Sign Up For FreeTo access detailed company insights
Praeventix was founded by Dr. Douglas Pippin based on discoveries he researched at Temple University. The company is initially focused on the development of pre-clinical candidate PRA-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. In addition, the company is researching 5-HT7 mod... Read More
